Chan Zuckerberg Initiative

What Chan Zuckerberg Initiative does

The Chan Zuckerberg Initiative (CZI) is a private philanthropy founded in 2015 by Priscilla Chan and Mark Zuckerberg, backed by a pledged $45 billion endowment in Meta shares and a 99% lifetime wealth commitment from its founders. Headquartered in Redwood City, California with approximately 875 employees, CZI operates across four legal structures — an LLC, a 501(c)(3) private foundation, a donor-advised fund at the Silicon Valley Community Foundation, and a 501(c)(4) advocacy organization — supporting work in science, education, and community. The organization has awarded approximately $7.22 billion in grants and invested nearly $300 million in ventures since inception.

In November 2025 CZI executed a major strategic pivot to concentrate resources on AI-powered biological research, making its Biohub network the central operating entity. Core scientific products include the Virtual Cells Platform (VCP), the CELLxGENE single-cell analysis tool, the Billion Cells Project for large-scale human cell reference data, and proprietary AI models: rBio (a reasoning model trained via "soft verification" on virtual simulations that outperformed lab-data-trained models in benchmarks), GREmLN (gene regulatory network modeling for cancer detection), and TranscriptFormer (cross-species generative cell atlas). These run on GPU-accelerated compute through an expanded NVIDIA partnership, with plans to scale to 10,000 GPUs by 2028, and are complemented by the Biohub Imaging Institute and the $20 million CRISPR Cures Center at the Innovative Genomics Institute.

The organization does not sell commercial products or services. Its business model is grantmaking — distributing funds through Requests for Applications to scientific researchers, rare disease patient-led networks (Rare As One), education partners (Gradient Learning / Summit Learning / Learning Commons), and 167 local nonprofit partners in San Mateo County and Kaua'i. Venture investments, open-source AI tool distribution, and capacity-building training for grantees round out the go-to-market motion. CZI acquired the EvolutionaryScale life-sciences AI team in November 2025, announced a $50 million Sacramento State AI center donation in February 2026, and recently cut roughly 8% of staff while terminating its FWD.us funding relationship to reallocate capital toward science.

Name

Chan Zuckerberg Initiative

Legal name

The Chan Zuckerberg Initiative

Website

http://chanzuckerberg.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Chan Zuckerberg Initiative is a private philanthropy founded in 2015 by Priscilla Chan and Mark Zuckerberg, backed by a $45 billion pledged endowment. It concentrates resources on AI-powered biological research through Biohub while funding rare disease, education, and community initiatives via grants and venture investments.

Ownership category

akta.pro rank

Product category

Philanthropy and Biomedical Research

NAICS

Software Publishers (5132), Software Publishers (51321)

akta.pro primary industry

Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

Keywords

• Biomedical research
• AI-powered biology
• Philanthropic grantmaking
• Virtual cell modeling
• Education technology

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Others

Revenue model

1. Philanthropic Endowment: Funded by Mark Zuckerberg and Priscilla Chan's pledged $45 billion in Meta shares. Since 2015, CZI has awarded approximately $7.22 billion in grants and invested nearly $300 million in ventures.
2. Wealth Pledge: Founders have pledged 99% of their wealth, primarily from Meta Platforms shares. Have donated $4 billion since 2016 with plans to double this over the next decade.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

CZI is a private philanthropy that funds and conducts AI-powered biomedical research, education technology development, and community grantmaking. Its primary operating vehicle is the Biohub, which develops virtual cell models, AI reasoning systems (rBio, GREmLN, TranscriptFormer), and single-cell analysis tools (CELLxGENE, Virtual Cells Platform) to accelerate disease cure and prevention. The organization also operates the Summit Learning education platform and Rare As One grant program supporting patient-led rare disease research networks.

Product overview

The Chan Zuckerberg Initiative operates as a philanthropy with a major strategic pivot toward AI-powered biological research through its Biohub organization. The core offering is the Biohub, a biomedical research organization developing virtual cell models and AI systems to understand and cure disease. Key products include the Virtual Cells Platform (VCP) for accessing AI models and biological data, CELLxGENE for single-cell data exploration, and specialized AI models including rBio (reasoning), GREmLN (gene networks), and TranscriptFormer (cross-species atlases). CZI also maintains education technology through Summit Learning in partnership with Gradient Learning, and supports rare disease research through the Rare As One grant program. The organization operates research facilities including the Biohub Imaging Institute for developing advanced microscopy technologies.

Differentiator

Problem solved

Functional benefit

Products and services

• Virtual Cells Platform (VCP) A platform for developing and adopting virtual cell models using AI tools, data, models, and benchmarks. The VCP enables researchers to access and work with computational models of cellular behavior for drug discovery and biological research, processing petabytes of biological data through GPU-accelerated infrastructure in partnership with NVIDIA.
• CELLxGENE A tool for exploring and analyzing single-cell biology datasets, enabling researchers to visualize and interrogate large-scale cellular data including 800,000+ human organoid cells forming color-coded tissue clusters. Used by biomedical scientists to visualize and analyze single-cell biology datasets.
• rBio An AI reasoning model trained on virtual cell simulations to reason about cellular biology, enabling computational hypothesis testing without laboratory experiments. The model uses a 'soft verification' approach and outperformed models trained on real lab data in benchmarks.
• GREmLN (Gene Regulatory Model Learner Network) An AI model for analyzing gene relationships and regulatory networks, helping scientists identify signs of cancer cells and understand gene expression patterns through computational modeling of gene regulatory networks.
• TranscriptFormer A generative AI model creating cross-species cell atlases, enabling researchers to explore and compare cellular data across different organisms and understand evolutionary relationships among species.
• Summit Learning An AI-powered education platform developed in partnership with Gradient Learning, providing tools that help teachers tailor instruction to meet individual student needs through learning science integration.

Quantifiable outcome

• First FDA-approved clinical gene therapy trial for FOXG1 syndrome beginning May 2026
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability10 records

Feature8 records

Partnerships

Ten partnerships are on record, tiered former, core, major and minor.

• FWD.usformerOthers · 19 December 2025Pro-immigration advocacy group co-founded by Mark Zuckerberg. CZI severed financial support in 2025 as part of strategic shift toward scientific research and AI.
• EvolutionaryScalecoreTechnology or Integration · 6 November 2025Acquisition of EvolutionaryScale's team as part of restructuring to unify scientific and research entities under Biohub. Company developed AI algorithms for life sciences.
• NVIDIAcoreTechnology or Integration · 31 October 2025Expanded collaboration to develop and adopt virtual cell models using AI tools, data, models, and benchmarks. Partnership aims to enhance biological data processing, increase data access, and develop large-scale virtual cell models. NVIDIA provides GPU-accelerated processing and technology expertise.
• Citizen HealthmajorStrategic or Co-development Partner · 21 November 2024$14.5 million seed funding round participation. AI-powered health platform for rare and complex conditions collaborating with CZI's Rare As One Project to build knowledge base for rare diseases and accelerate drug development.
• Kavli FoundationmajorStrategic or Co-development Partner · 27 June 2024Partnership with Wellcome Trust and Research Software Alliance to fund open-source neuroscience software through Essential Open Source Software for Science (EOSS) grant program.
• Wellcome TrustmajorStrategic or Co-development Partner · 27 June 2024Co-funding partner for Essential Open Source Software for Science (EOSS) program supporting software maintenance, growth, development, and community engagement for critical open source scientific tools.
• BiohubcoreStrategic or Co-development PartnerCore biomedical research organization bringing together scientists, engineers, and AI experts. Central entity receiving majority of CZI resources following November 2025 strategic pivot. Mission to help scientists cure or prevent all disease.
• Gradient LearningmajorStrategic or Co-development PartnerEducation partnership to build tools empowering teachers to meet individual student needs. CZI provides pro bono technology support while Gradient Learning enforces privacy and security policies.
• Bill & Melinda Gates FoundationminorStrategic or Co-development PartnerBoth cited as leading examples of philanthropists reshaping funding landscape for applied science with documented achievements including polio eradication and malaria vaccine development.
• Breakthrough EnergyminorStrategic or Co-development PartnerCited alongside CZI and Gates Foundation as leading model of philanthropists providing risk tolerance and strategic vision for applied science.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Howard Hughes Medical Institute: HHMI is a major non-profit biomedical research organization with a multi-billion endowment supporting scientists at the frontier of disease research. Comparable to CZI in structure (private philanthropy funding long-horizon biomedical science), scale, and direct-investigator support model.
• Wellcome Trust: One of the largest charitable foundations globally, funding biomedical research and public health. Directly comparable to CZI in operating model (large endowment funding science grants), scale, and global scientific footprint. CZI co-funds the EOSS program with Wellcome.
• Bill & Melinda Gates Foundation: Largest private philanthropy globally, with substantial science and global health funding. Cited alongside CZI in the data as a leading example of philanthropist-led science funding. Similar endowment-driven, multi-decade mission approach.
• Arc Institute: Palo Alto-based non-profit research organization co-founded by Patrick Collison in 2021, focused on complex human disease research combining experimental and computational biology. Direct competitor in the AI-for-biology research space and geographically co-located with CZI's Biohub.
• Allen Institute: Non-profit research organization founded by Paul Allen, conducting large-scale science projects (brain science, cell science, AI) with open-science principles. Closely comparable to CZI in mission structure (philanthropy-funded research institute producing open datasets and tools).
• Schmidt Sciences: Philanthropic entity of Eric Schmidt funding frontier science including AI and biosciences. Comparable structure as large-scale philanthropy funding both scientific research and AI tooling, with similar emphasis on long-horizon, capital-intensive projects.
• Broad Institute: Joint Harvard-MIT research organization focused on genomics, disease biology, and computational methods. Highly comparable to CZI's Biohub in producing large-scale biological datasets (analogous to Billion Cells Project) and developing computational tools for biomedicine.

Emerging players

• Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology for therapeutic development. Comparable to CZI's Biohub in applying AI to biology, though operating as a commercial venture rather than a non-profit.
• Recursion Pharmaceuticals: Public biotech using AI and high-throughput biology for drug discovery, with significant compute infrastructure. Operates at the intersection of AI and biology similar to CZI's Biohub, with comparable ambition around data-driven biological modeling.

Broad incumbents

• DeepMind (Alphabet): Alphabet-owned AI research lab with significant life sciences work (AlphaFold, AlphaFold 3, Isomorphic Labs). Directly comparable to CZI's virtual cell and protein-modeling ambitions, though operates as part of a much larger commercial parent with broader AI scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ChanZuckerberg
• Facebookfacebook.com/chanzuckerberginitiative
• LinkedInlinkedin.com/company/chan-zuckerberg-initiative

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments73 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chan Zuckerberg Initiative